Tumor Suppressor Proteins

"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.

Descriptor ID	D025521
MeSH Number(s)	D12.776.624.776
Concept/Terms	Tumor Suppressor Proteins Tumor Suppressor Proteins Proteins, Tumor Suppressor Metastasis Suppressor Proteins Metastasis Suppressor Proteins Proteins, Metastasis Suppressor Growth Suppressor Proteins Growth Suppressor Proteins Proteins, Growth Suppressor

Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Neoplasm Proteins [D12.776.624]
Tumor Suppressor Proteins [D12.776.624.776]

Below are MeSH descriptors whose meaning is related to "Tumor Suppressor Proteins".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.

Bar chart showing 175 publications over 29 distinct years, with a maximum of 11 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	5	1	6
1998	3	1	4
1999	9	1	10
2000	4	0	4
2001	2	2	4
2002	1	7	8
2003	7	3	10
2004	3	5	8
2005	6	4	10
2006	3	2	5
2007	9	2	11
2008	4	6	10
2009	4	1	5
2010	4	4	8
2011	6	4	10
2012	6	2	8
2013	5	4	9
2014	2	1	3
2015	7	2	9
2016	2	0	2
2017	2	2	4
2018	2	3	5
2019	2	0	2
2020	1	2	3
2021	2	4	6
2022	3	2	5
2023	0	1	1
2024	2	1	3

Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.

Lee JC, Koo SC, Furtado LV, Breuer A, Eldomery MK, Bag AK, Stow P, Rose G, Larkin T, Sances R, Kleinschmidt-DeMasters BK, Bodmer JL, Willard N, Gokden M, Dahiya S, Roberts K, Bertrand KC, Moreira DC, Robinson GW, Mo JQ, Ellison DW, Orr BA. Concurrent ependymal and ganglionic differentiation in a subset of supratentorial neuroepithelial tumors with EWSR1-PLAGL1 rearrangement. Acta Neuropathol Commun. 2024 09 03; 12(1):143.

View in: PubMed
Chua V, Lopez-Anton M, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T, Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Sci Signal. 2024 06 11; 17(840):eadn8376.

View in: PubMed
Eiger-Moscovich M, Shields CL, Eagle RC, Milman T. BRCA-associated protein1 (BAP1) immunohistochemical stain reliability in postbrachytherapy uveal melanoma enucleation specimens. Indian J Ophthalmol. 2024 05 01; 72(Suppl 3):S459-S467.

View in: PubMed
Thomas S, Dilbarov N, Kelly J, Mercogliano G, Prendergast GC. Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis. Sci Rep. 2023 07 21; 13(1):11802.

View in: PubMed
Thomas S, Mercogliano G, Prendergast GC. Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment. PLoS One. 2022; 17(11):e0276910.

View in: PubMed
Langbein LE, El Hajjar R, He S, Sementino E, Zhong Z, Jiang W, Leiby BE, Li L, Uzzo RG, Testa JR, Yang H. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma. Cancer Lett. 2022 10 28; 547:215885.

View in: PubMed
Baqai U, Purwin TJ, Bechtel N, Chua V, Han A, Hartsough EJ, Kuznetsoff JN, Harbour JW, Aplin AE. Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma. Mol Cancer Res. 2022 08 05; 20(8):1260-1271.

View in: PubMed
Wu D, Chapela PJ, Barrows CML, Harrington DA, Carson DD, Witt RL, Mohyuddin NG, Pradhan-Bhatt S, Farach-Carson MC. MUC1 and Polarity Markers INADL and SCRIB Identify Salivary Ductal Cells. J Dent Res. 2022 07; 101(8):983-991.

View in: PubMed
Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE. Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma. Oncogene. 2022 Feb; 41(8):1129-1139.

View in: PubMed
Hu ZI, Miettinen M, Quezado M, Lebensohn AP, Aldape K, Agra M, Wagner C, Mallory Y, Hassan R, Ghafoor A. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations. J Thorac Oncol. 2022 03; 17(3):461-466.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement